Euroopa Liit - eesti - EMA (European Medicines Agency)

bene-arzneimittel gmbh - naatriumpentosaanpolüsulfaat - tsüstiit, interstitsiaalne - uroloogilised ravimid - elmiron on näidustatud põievalu sündroomi raviks, mida iseloomustavad kas glomerulatsioonid või hunneri kahjustused mõõduka kuni raske valu, kiireloomulisuse ja urineerimissageduse korral täiskasvanutel.

Eesti - eesti - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 20mg 60tk; 20mg 84tk; 20mg 28tk; 20mg 90tk; 20mg 30tk; 20mg 100tk; 20mg 10tk; 20mg 98tk; 20mg 56tk

Eesti - eesti - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 90tk; 10mg 60tk; 10mg 84tk; 10mg 14tk; 10mg 20tk; 10mg 98tk; 10mg 56tk; 10mg 10tk

Eesti - eesti - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 80mg 30tk; 80mg 98tk; 80mg 50tk; 80mg 56tk; 80mg 28tk; 80mg 84tk; 80mg 100tk; 80mg 10tk

Eesti - eesti - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 40mg 50tk; 40mg 14tk; 40mg 10tk; 40mg 28tk; 40mg 30tk; 40mg 20tk; 40mg 84tk; 40mg 90tk

Eesti - eesti - Ravimiamet

scandic pharma sia - atorvastatiin - õhukese polümeerikattega tablett - 20mg 30tk

Eesti - eesti - Ravimiamet

scandic pharma sia - atorvastatiin - õhukese polümeerikattega tablett - 10mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan s.a.s. - pregabaliin - anxiety disorders; neuralgia; epilepsy - antiepileptics, - epilepsypregabalin mylan pharma on näidustatud adjunctive ravi täiskasvanutel, osaline krambid koos või ilma sekundaarse üldistada. generaliseerunud Ärevus disorderpregabalin mylan pharma on näidustatud ravi generaliseerunud Ärevushäire (gad) täiskasvanutel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Eesti - eesti - Ravimiamet

teva b.v. - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 7tk; 20mg 100tk; 20mg 98tk; 20mg 42tk; 20mg 14tk; 20mg 250tk; 20mg 56tk; 20mg 60tk; 20mg 28tk